Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare

Cellecta  

Charles River Discovery

Elsevier 

 NanoString     

 SeraCare 

Silicon Biosystems   

 Streck 

 TriMetis


XIFIN

  View All Sponsors 

Dinner Short Course

Building an Investigational Program to Establish the Clinical Value of a Test  


Sunday, February 9, 2014 | 2:30 - 5:30 pm | Moscone North Convention Center | San Fransisco, CA 


Building an Investigational Program to Establish the Clinical Value of a Test   

Instructors: 

Catherine SchnabelCatherine Schnabel, Ph.D., Vice President, Medical, Clinical & Regulatory Affairs, bioTheranostics, Inc. 

 

 

 

 

 

 

Brock SchroederBrock Schroeder, Ph.D., Director, Medical & Scientific Affairs, bioTheranostics Inc. 

 

 

 

 

 

 

Development of a strong clinical program for diagnostic tests requires consideration and integration of key strategic drivers such as clinical adoption, reimbursement, & regulatory filing based on a proposed indication for use.  In considering the appropriate use of new tests, clinicians and health care policymakers must consider the accuracy with which a test identifies a patient’s clinical status (clinical validity), the risks and benefits resulting from test use (clinical utility), and the medical value of the test (health economics/outcomes). This workshop will provide a basic framework for establishing comprehensive clinical evidence based on analytical validity, clinical validity, clinical utility, and health economics and effectiveness, and utilize a case study of the 92-gene assay, CancerTYPE ID to build these points.

  • Clinical study designs for biomarker research/Levels of evidence
  • Formulating clinical endpoints
  • Framework for clinical evidence
  • Data requirements for various stakeholders
  • Case study

 

 

Back To Short Courses